These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 12739985)

  • 61. Ximelagatran: pharmacokinetics and pharmacodynamics of a new strategy for oral direct thrombin inhibition.
    Kereiakes DJ
    Rev Cardiovasc Med; 2004; 5 Suppl 5():S4-11. PubMed ID: 15619615
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Intestinal and hepatobiliary transport of ximelagatran and its metabolites in pigs.
    Sjödin E; Fritsch H; Eriksson UG; Logren U; Nordgren A; Forsell P; Knutson L; Lennernäs H
    Drug Metab Dispos; 2008 Aug; 36(8):1519-28. PubMed ID: 18458048
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects.
    Stangier J; Stähle H; Rathgen K; Fuhr R
    Clin Pharmacokinet; 2008; 47(1):47-59. PubMed ID: 18076218
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Melagatran and ximelagatran: new drug. No real simplification of anticoagulant therapy.
    Prescrire Int; 2005 Aug; 14(78):127-32. PubMed ID: 16106594
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effect of low and high dose melagatran and other antithrombotic drugs on platelet aggregation.
    Soslau G; Ando A; Floyd L; Hong T; Mathew L; Yen Y
    J Thromb Thrombolysis; 2008 Apr; 25(2):198-203. PubMed ID: 17710375
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT.
    Eriksson H; Eriksson UG; Frison L; Hansson PO; Held P; Holmström M; Hägg A; Jonsson T; Lapidus L; Leijd B; Stockelberg D; Säfwenberg U; Taghavi A; Thorsén M
    Thromb Haemost; 1999 Mar; 81(3):358-63. PubMed ID: 10102460
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effects of the oral direct thrombin inhibitor ximelagatran on p-selectin expression and thrombin generation in atrial fibrillation.
    Wolzt M; Boström SL; Svensson M; Wåhlander K; Grind M; Sarich TC
    Pathophysiol Haemost Thromb; 2003; 33(2):68-74. PubMed ID: 14624047
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Ximelagatran: direct thrombin inhibitor.
    Ho SJ; Brighton TA
    Vasc Health Risk Manag; 2006; 2(1):49-58. PubMed ID: 17319469
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A combination of a thrombin inhibitor and dexamethasone prevents the development of experimental disseminated intravascular coagulation in rats.
    Elg M; Gustafsson D
    Thromb Res; 2006; 117(4):429-37. PubMed ID: 15869787
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Acute antithrombotic effects of ximelagatran, an oral direct thrombin inhibitor, and r-hirudin in a human ex vivo model of arterial thrombosis.
    Sarich TC; Osende JI; Eriksson UG; Fager GB; Eriksson-Lepkowska M; Ohlsson L; Carlsson S; Wåhlander K; Gustafsson D; Badimon JJ
    J Thromb Haemost; 2003 May; 1(5):999-1004. PubMed ID: 12871368
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effects of melagatran on activated partial thromboplastin time and on ecarin clotting time in cord versus adult plasma.
    Koestenberger M; Gallistl S; Bettina L; Cimenti C; Kutschera J; Cvirn G
    Blood Coagul Fibrinolysis; 2006 Nov; 17(8):677-80. PubMed ID: 17102656
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Melagatran and ximelagatran. Pharmacologic characteristics and anesthesiological aspects].
    Pindur G; Ziegeler S; Kleinschmidt S
    Anaesthesist; 2003 Dec; 52(12):1171-5. PubMed ID: 14691631
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Ximelagatran, a new oral direct thrombin inhibitor, for the prevention of venous thromboembolic events in major elective orthopaedic surgery. Efficacy, safety and anaesthetic considerations.
    Rosencher N
    Anaesthesia; 2004 Aug; 59(8):803-10. PubMed ID: 15270973
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The METHRO trials.
    Hamaad A; Tayebjee MH; Lip GY
    Expert Opin Investig Drugs; 2003 May; 12(5):865-70. PubMed ID: 12720496
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation.
    Halperin JL
    J Am Coll Cardiol; 2005 Jan; 45(1):1-9. PubMed ID: 15629364
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Ximelagatran in orthopaedic surgery.
    Eriksson B
    Pathophysiol Haemost Thromb; 2005; 34 Suppl 1():10-7. PubMed ID: 15812199
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The effects of ximelagatran and warfarin on the prophylaxis of a caval vein thrombosis and bleeding in the anaesthetized rat.
    Carlsson S; Elg M
    Blood Coagul Fibrinolysis; 2005 Jun; 16(4):245-9. PubMed ID: 15870543
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Ximelagatran: a novel oral direct thrombin inhibitor for long-term anticoagulation.
    McCullough PA; Dorrell KA; Sandberg KR; Yerkey MW
    Rev Cardiovasc Med; 2004; 5(2):99-103. PubMed ID: 15184843
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C; Mouret P
    Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.
    Schulman S; Wåhlander K; Lundström T; Clason SB; Eriksson H;
    N Engl J Med; 2003 Oct; 349(18):1713-21. PubMed ID: 14585939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.